The incidence of bronchial asthma (BA), chronic obstructive pulmonary disease (COPD) and other respiratory diseases was diminished in patients receiving SGLT2 inhibitors across various treatment regimens [245]. Here, SLC5A2 is linked to chronic obstructive pulmonary disease.